16 completed. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 2 | Completed 2 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers Aprepitant 125 mg - Healthy | Phase 1 | Completed | Nuformix Technologies Limited | 12 | 2019-03-20 | 2020-02-25 |
| Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers Aprepitant Capsule 125 MG, Aprepitant oral suspension 20 mg/mL - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | The Hospital for Sick Children | 17 | 2017-08-10 | 2022-04-11 |
| Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying Aprepitant, Placebo - Healthy | Phase 1 | Completed | Mayo Clinic | 27 | 2017-01-27 | 2018-12-12 |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers bosutinib or bosutinib + aprepitant - Healthy | Phase 1 | Completed | Pfizer | 20 | 2014-05-01 | 2014-06-24 |
| Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects Aprepitant - HIV Infection | Phase 1 | Completed | University of Pennsylvania | 12 | 2014-05-01 | 2017-08-17 |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas TRC102, CT scan, Lomotil - Lymphomas, Solid Tumors | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2013-07-12 | 2024-05-08 |
| Aprepitant Effects in Intravenous Heroin Dependence Aprepitant, Placebo pill - Opioid Dependence | Phase 1 | Completed | NYU Langone Health | 64 | 2012-01-01 | 2021-08-23 |
| Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose Aprepitant, Aprepitant placebo - HIV Infection | Phase 1 | Completed | University of Pennsylvania | 18 | 2010-12-01 | 2016-06-03 |
| Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2010-04-01 | 2015-02-25 |
| A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 42 | 2009-02-01 | 2015-01-28 |
| A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) Aprepitant, Ondansetron - Postoperative Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 98 | 2009-01-26 | 2021-01-26 |
| Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals Placebo, Aprepitant - HIV Infections | Phase 1 | Completed | University of Pennsylvania | 30 | 2007-01-01 | 2017-03-30 |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) SCH 727965, Aprepitant, Ondansetron - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 81 | 2006-10-11 | 2017-10-23 |
| Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer aprepitant, cyclophosphamide, placebo - Breast Cancer, Nausea and Vomiting | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 19 | 2005-08-01 | 2024-11-04 |
| A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam - Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 188 | 2005-01-01 | 2015-08-19 |
Vomiting (5) · HIV Infections (3) · Postoperative Nausea and Vomiting (2) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Glioblastoma (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Nausea (1) · Opioid-Related Disorders (1)
Merck Sharp & Dohme LLC (5) · University of Pennsylvania (3) · Mayo Clinic (1) · NYU Langone Health (1) · National Cancer Institute (NCI) (1) · Nuformix Technologies Limited (1) · Pfizer (1) · The Hospital for Sick Children (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Ulm (1)
United States (9) · Brazil (1) · Canada (1) · Germany (1) · Mexico (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Pablo Tebas, MD (3) · Alice P Chen, M.D. (1) · Christine M. Walko, PharmD, BCOP (1) · Marc-Eric Halatsch, MD (1) · Michael Camilleri (1) · Stephen Ross, MD (1)
PMID 21931661, PMID 22245954, PMID 22739139, PMID 23053255, PMID 25915168, PMID 27121336, PMID 27718000, PMID 28859059, PMID 28978797, PMID 31694495, PMID 32839657, PMID 34620071, PMID 34959641, PMID 38396172
U01MH090325 (2), 2008 (1), P30CA016086 (1), R01DA027151 (1)